Home » Advocacy » Letters, Testimony & Comments

Letters, Testimony & Comments

To Representative John Conyers
March 21, 2002
Ranking Member of the House Judiciary Committee
To Representative Howard Coble
March 21, 2002
Chairman of the House Judiciary Subcommittee on Courts, The Internet, and Intellectual Property
To Representative Howard Berman
March 21, 2002
Ranking Member of the House Judiciary Subcommittee on Courts, The Internet, and Intellectual Property
BIO letters outlining opposition to HR 3967, The Genomic Research and Diagnostic Accessibility Act of 2002
March 21, 2002
Supporting the Passage of Trade Promotion Authority Without Accompanying Amendments
March 6, 2002
Letter, United States Senate
Reauthorization of the Prescription Drug User Fee Act
March 6, 2002
Mr. Chairman and Members of the Subcommittee, I am Mary K. Pendergast, Executive Vice President for Government Affairs at Elan Pharmaceuticals Management Corporation. I am pleased to be here today on behalf of the Biotechnology Industry...
BIO Supports the Biological and Chemical Weapons Research Act
March 3, 2002
BIO supports S. 1764, the Robert Stevens, Thomas Morris Jr., Joseph Curseen, Kathy Nguyen, Ottilie Lundgren, and Lisa Raines Biological and Chemical Weapons Research Act as introduced by Senator Joseph Lieberman. (Mar. 3, 2002).
Law and Policy in the Knowledge E-Based Economy
February 26, 2002
The biotechnology industry is the most research and development intensive and capital-focused industry in the world. As such, it is very dependent on a robust intellectual property system as well as a strong set of competition laws. Recent...
BIO Director Testifies In Senate Hearing
February 5, 2002
Testimony of Dr. Una S. Ryan President and CEO, AVANT Immunotherapeutics, Inc. Before the Subcommittee on Science, Technology, and Space Senate Committee on Commerce, Science, and Transportation Tuesday, February 5, 2002   Mr....
History of Pediatric Studies, Rule, Legislation and Litigation
January 8, 2002
FDA's Pediatric Rule Early Rule. In 1994 FDA issued a regulation requiring manufacturers of marketed drugs to survey existing data and to determine whether the data were sufficient to support additional pediatric use information in the...
Eli Lilly and Company v. Barr Laboratories Inc. Petition for a writ of certiorari filed
December 13, 2001
For the second time this year, BIO along with PhRMA filed a petition for a write of certiorari before the Supreme Court. The petition filed on Thursday Eli Lilly and Company v. Barr Laboratories Inc., asks the Supreme Court to address and correct...
J.E.M AG Supply, Inc. v. Pioneer Hi-Bred
December 10, 2001
On December 10th, 2001, the Supreme Court held that Utility patents may be issued for plants under 35 U.S.C. 101 despite distinct protections available under the Plant Variety Protection Act and the Plant Patent Act. Affirming the Federal Circuit...
FDA Stakeholders Meeting
December 7, 2001
Good morning. My name is Michael Werner. I am Vice President for Bioethics for the Biotechnology Industry Organization (BIO). BIO represents more than 1,000 biotechnology companies and academic institutions in all 50 states. More than 90 percent...
Letter to Carl B. Feldbaum, BIO President from Samual W. Bodman, Deputy Secretary of Commerce
November 15, 2001
Regarding funding for the U.S. Patent and Trademark Office
BIO letter to J. Dennis Hastert
November 5, 2001
Economic Fundamentals Sound: Deal-Making within the Biotechnology Industry
October 29, 2001
By Carl B. Feldbaum At a time when national security is understandably monopolizing Congress's legislative calendar, as well as the energies of the federal agencies that regulate biotechnology, I am pleased to report that the biotechnology...
Testimony of Stephen G. Sudovar President & CEO, EluSys Therapeutics, Inc.
October 23, 2001
TESTIMONY OF STEPHEN G. SUDOVAR President and CEO EluSys Therapeutics, Inc. 10 Bloomfield Ave. Pine Brook, NJ 07058 973-808-0222 (phone) 973-808-0322 (fax) Committee on Government Reform Subcommittee on National Security, Veterans Affairs...
Testimony of Una S. Ryan, Ph.D., President & CEO, AVANT Immunotherapeutics, Inc.
October 23, 2001
TESTIMONY U.S. House of Representatives Committee on Government Reform Subcommittee on National Security, Veterans Affairs, and International Relations Hearing on Biological Warfare Defense Vaccine Research & Development Programs 10:00 A...
BIO letter to US House of Representatives Energy and Commerce Chairman Tauzin
October 1, 2001
Outling BIO opposition to generic biologic and pediatric rule codification amendments on pediatric exclusity bill.
BIO letter to US House of Representatives Energy and Commerce Health Subcommittee Chairman Bilirakis
October 1, 2001
Outlining BIO opposition to generic biologic and pediatric rule codification amendments on pediatric exclusivity bill